What AbbVie (ABBV)'s Phase 3 Lymphoma Win Means For Shareholders

AbbVie and Genmab reported that epcoritamab plus R-CHOP achieved statistically significant Phase 3 progression-free survival results in newly diagnosed high-risk DLBCL, with safety in line with the known profiles of the component therapies. The epcoritamab outcome adds another late-stage oncology asset alongside AbbVie’s expanding immunology portfolio and reinforces how clinical execution is reshaping its mix beyond legacy therapies like Humira and Imbruvica. Next, the focus shifts to how...